Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MDM4 | O15151 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11912033 | 0.89 | HDAC1 (0.54) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL31000548 | 0.89 | HDAC1 (0.54) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL28527138 | 0.89 | HDAC1 (0.54) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL29397673 | 0.89 | HDAC1 (0.54) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL13402442 | 0.89 | HDAC1 (0.54) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL17446653 | 0.88 | PTPN1 (0.48) | HDAC1HDAC2MDM4TP53TNF | |
| SCHEMBL23811055 | 0.88 | HDAC1 (0.53) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL31348963 | 0.88 | CASP3 (0.55) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL31348914 | 0.88 | CASP3 (0.55) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL6588912 | 0.88 | CASP3 (0.55) | HDAC1HDAC2IDO1KMT2AMDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210778-A1 | NOVEL COMPOUNDS | INVIVOGEN SAS (FR) | 2017-07-27 | — | — | US | disclosed |
| WO-2016008946-A1 | NOVEL COMPOUNDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2016-01-21 | — | — | WO | disclosed |
| EP-2975046-A1 | Novel compounds | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth (IE) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210778-A1 | NOVEL COMPOUNDS | F12, C1R, F11 | HDAC1 747/4885HDAC2 1296/4885IDO1 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.